June 2026 · 7 min read
NAD+ and the mitochondrion: the electron carrier before the sirtuin
A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
The popular account of NAD+ starts with sirtuins. It is the wrong end of the molecule's biology. Sirtuins consume NAD+ as a substrate for a signalling reaction, and they are interesting; but the reason a cell keeps NAD+ in the first place is that it cannot make ATP without it.
NAD+ is, first and foremost, an electron carrier for mitochondrial energy production. Everything else it does is built on top of that, and the mitochondrial literature is where the compound's biology is least speculative.
What the molecule actually carries
Mitochondria produce most of the ATP in most cell types, through oxidative phosphorylation. Substrates from glucose, fatty acid and amino acid metabolism are oxidised; the electrons released are passed along a series of protein complexes in the inner membrane — the electron transport chain — with oxygen as the terminal acceptor, and the energy released drives ATP synthesis.
Something has to move those electrons from the substrate to the chain. NAD+ is that something. It accepts electrons from a substrate being oxidised, becoming NADH, hands them to the start of the transport chain, and becomes NAD+ again. The NAD+/NADH couple cycles continuously, which is why a cell's total NAD+ content is small relative to the throughput it supports, and why availability rather than abundance is the thing that limits anything.
The pools are separate, and that is a design constraint
NAD+ is not distributed evenly through a cell. Separate pools are maintained in different compartments, each with its own regulation and its own decline pattern with age.
| Compartment | What the pool supports |
|---|---|
| Mitochondria | Electron transport chain, TCA cycle dehydrogenases, fatty acid oxidation, the mitochondrial sirtuins SIRT3, SIRT4 and SIRT5 |
| Cytoplasm | Glycolytic NAD+/NADH cycling, cytoplasmic NAD+-dependent enzymes, part of the SIRT1 and SIRT2 activity |
| Nucleus | Nuclear sirtuin reactions — SIRT1, SIRT6, SIRT7 — and PARP activity, from a smaller pool |
For anyone designing an experiment, this is the point that matters most and is most often skipped: a measurement of whole-cell NAD+ tells you very little about the mitochondrial pool, and an intervention that raises one need not raise the other. The mitochondrial pool is the one that rate-limits both bioenergetic function and SIRT3 activity, and mitochondrial dysfunction is one of the recognised hallmarks of ageing — the framework set out by López-Otín and colleagues (PMID 23746838).
What the mitochondrial work examines
Four endpoint families carry most of this literature, in cell culture and in rodents.
Respiratory function. Oxygen consumption, measured directly, which is the closest available read-out of oxidative phosphorylation activity. Ageing is associated with declining mitochondrial respiration, and studies have examined whether NAD+ repletion shifts respiration back toward a younger pattern.
Biogenesis markers. Mitochondrial DNA copy number and the expression of PGC-1α and the other transcription factors that govern the production of new mitochondria. These intersect NAD+ biology partly through sirtuin-dependent regulation, which is why the bioenergetic and sirtuin threads cannot be fully separated.
Quality control. Damaged mitochondria are cleared by mitophagy, a targeted form of autophagy, and the mitochondrial arm of it is SIRT3-dependent. Work here examines whether NAD+ availability changes how efficiently the clearance runs.
Protein deacetylation and oxidative stress. SIRT3 is the major mitochondrial sirtuin and deacetylates a long list of mitochondrial proteins, including TCA cycle enzymes, components of the phosphorylation machinery, and antioxidant defences such as SOD2. Since mitochondria are themselves a principal source of reactive oxygen species, this is where the bioenergetic and the protective functions meet.
Why decline hits mitochondria hardest
The age-related fall in NAD+ is not evenly distributed in its consequences, and the reason is a feedback loop rather than a single step.
Mitochondria are heavy consumers of NAD+, through the transport chain, the TCA cycle and SIRT3. Mitochondrial salvage is separately regulated, so it can be impaired while the cytoplasmic supply holds. Less mitochondrial NAD+ means less SIRT3 activity, and less SIRT3 activity means weaker antioxidant defence and less efficient clearance of damaged organelles. Damaged mitochondria produce less ATP and more reactive oxygen species, which damages mitochondria.
That loop is why mitochondrial dysfunction and NAD+ decline are usually described together. It is also why a single-timepoint measurement in an aged tissue cannot say which came first.
NAD+ and MOTS-c engage this from opposite ends
MOTS-c is a mitochondrial-derived peptide also studied in mitochondrial biology, but it is a signalling molecule: the published mechanism is AMPK activation. NAD+ is the substrate the machinery runs on. One tells the cell about its energy state; the other is part of how that state is produced.
A design can use both; neither is a version of the other.
Where the evidence stops
This is the section the popular account omits, and it is longer than it looks.
Most of the literature cited for 'NAD+ supplementation' is about precursors, not NAD+. Yoshino, Baur and Imai's review is explicitly about NMN and NR — the intermediates — and their biology and therapeutic potential (PMID 29249689). NMN and NR enter the salvage pathway at different points, and NAD+ administered as NAD+ is not interchangeable with either. When a claim about 'NAD+' is traced back, it frequently lands on a precursor study.
The anchor references are reviews. Verdin's 2015 Science piece (PMID 26785480) and Covarrubias and colleagues' 2021 review in Nature Reviews Molecular Cell Biology (PMID 33353981) summarise a field; they do not report an experiment. Reviews are the right way to learn what a literature contains and the wrong thing to cite for a specific result.
The experimental work is cell culture and rodent. Respirometry in cultured cells, mitochondrial function assays in mice. That is the whole base.
There is no human trial of NAD+ for mitochondrial endpoints. Not a small one, not an equivocal one — none that would settle any of the questions above.
Nothing here is approved. Neither NAD+ nor its precursors are approved drugs in Canada, the United States or the European Union for any indication. Health Canada, the FDA and the EMA have assessed none of them for this purpose. That some precursors are sold as supplements in some jurisdictions is a regulatory category, not a finding.
Nothing here is medical, dosing, or therapeutic guidance.
NAD+ is supplied here as NAD+, in two vial masses — 500mg and 1000mg. Janoshik-verified by HPLC with mass-spec identity confirmation; 100% synthetic. The measured purity for each lot is stated on its product page. For laboratory research use only.
Common questions
Is mitochondrial NAD+ research the same as NAD+ longevity research? Related, not the same. The mitochondrial work measures bioenergetic endpoints — respiration, biogenesis, mitochondrial DNA, ATP. The longevity framing usually measures sirtuin-dependent outputs. They overlap at SIRT3 and at mitochondrial biogenesis, and diverge everywhere else.
Why does NAD+ matter more to mitochondria than elsewhere? Because the electron-carrier role is its primary biological function and most of that function happens inside mitochondria. The organelle is also a heavy consumer of the pool it depends on, which makes it the first place a shortage shows.
Is the mitochondrial pool really separate from the cytoplasmic one? Yes. The compartments are separately maintained and separately regulated, which is why a whole-cell NAD+ figure is a weak proxy for the thing most of this research is actually about.
Why does mitochondrial NAD+ fall with age? Several contributions are described in the reviews: declining salvage capacity, higher consumption by inflammatory and repair pathways, NNMT activity diverting nicotinamide to excretion, and broader metabolic dysregulation. They reinforce one another, which is what makes the decline difficult to attribute to any one of them.
Selected Research References
- Verdin E. NAD+ in Aging, Metabolism, and Neurodegeneration. Science. 2015;350(6265):1208-1213. pubmed.ncbi.nlm.nih.gov/26785480
- Yoshino J, Baur JA, Imai SI. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metabolism. 2018;27(3):513-528. pubmed.ncbi.nlm.nih.gov/29249689
- Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ Metabolism and Its Roles in Cellular Processes during Ageing. Nature Reviews Molecular Cell Biology. 2021;22(2):119-141. pubmed.ncbi.nlm.nih.gov/33353981
- López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The Hallmarks of Aging. Cell. 2013;153(6):1194-1217. pubmed.ncbi.nlm.nih.gov/23746838
- Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metabolism. 2018;27(3):529-547.
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.